TABLE 2.
Comparison of STICH Hypothesis 1 Patients with vs. without Genetic Data
| Characteristic | No Genetic Data (n=604) | Genetic Data (n=532) | P Value |
|---|---|---|---|
| Age, median (25th, 75th), yrs. | 57.8 (52.5, 65.8) | 61.2 (54.8, 69.1) | <0.001 |
| Female, no. (%) | 67 (11.1%) | 72 (13.5%) | 0.210 |
| White race | 281 (46.5%) | 476 (89.5%) | <0.001 |
| Minority (Hispanic or racial minority) | 347 (57.5%) | 66 (12.4%) | <0.001 |
| BMI | 26.1 (23.3, 29.5) | 27.4 (24.5, 30.2) | <0.001 |
| Previous MI, no. (%) | 460 (76.2%) | 410 (77.1%) | 0.718 |
| Previous stroke, no. (%) | 29 (4.8%) | 56 (10.5%) | <0.001 |
| Diabetes, no. (%) | 229 (37.9%) | 226 (42.5%) | 0.117 |
| Hypertension, no. (%) | 353 (58.4%) | 338 (63.5%) | 0.080 |
| Hyperlipidemia, no. (%) | 313 (51.8%) | 361 (68.0%) | <0.001 |
| Current smoker | 128 (21.2%) | 100 (18.8%) | 0.308 |
| Chronic renal insufficiency, no. (%) | 39 (6.5%) | 48 (9.0%) | 0.105 |
| Peripheral vascular disease | 86 (14.2%) | 89 (16.7%) | 0.246 |
| Atrial fibrillation/flutter | 58 (9.6%) | 85 (16.0%) | 0.001 |
| Previous PCI, no. (%) | 55 (9.1%) | 82 (15.4%) | 0.001 |
| Previous CABG, no. (%) | 20 (3.3%) | 16 (3.0%) | 0.771 |
| Current CCS angina class, no. (%) | <0.001 | ||
| No angina | 175 (29.0%) | 242 (45.5%) | |
| I | 80 (13.2%) | 94 (17.7%) | |
| II | 322 (53.3%) | 170 (32.0%) | |
| III | 21 (3.5%) | 22 (4.1%) | |
| IV | 6 (1.0%) | 4 (0.8%) | |
| Current NYHA heart failure class, no. (%) | 0.012 | ||
| I | 58 (9.6%) | 73 (13.7%) | |
| II | 304 (50.3%) | 281 (52.8%) | |
| III | 230 (38.1%) | 161 (30.3%) | |
| IV | 12 (2.0%) | 17 (3.2%) | |
| Creatinine | 1.1 (1.0, 1.2) | 1.1 (0.9, 1.3) | 0.587 |
| Risk at randomization | 10.5 (5.0, 19.0) | 13.0 (5.0, 20.0) | 0.027 |
| No. of diseased vessels (≥75% stenosis), no. (%) | 0.151 | ||
| 1 | 136 (22.5%) | 143 (26.9%) | |
| 2 | 236 (39.1%) | 197 (37.1%) | |
| 3 | 232(38.4%) | 191 (36.0%) | |
| Left main (≥50% stenosis), no. (%) | 14 (2.3%) | 16 (3.0%) | 0.466 |
| Proximal LAD (≥75% stenosis), no. (%) | 432 (71.5%) | 333(62.7%) | 0.002 |
| LV ejection fraction, median (25th, 75th), % | 28.0 (22.9, 34.0) | 27.0 (22.0, 33.4) | 0.260 |
| ESVI, median (25th, 75th), mL/m2 | 76.6 (58.4, 97.0) | 81.8 (63.0, 105.3) | 0.005 |
| Mitral regurgitation | 0.326 | ||
| None or trace | 197 (32.7%) | 207 (39.1%) | |
| Mild (≤2+) | 306 (50.7%) | 218 (41.1%) | |
| Moderate or severe | 100 (16.6%) | 105 (19.8%) | |
| Region, no. (%) | <0.001 | ||
| Europe | 312 (51.7%) | 319 (60.0%) | |
| US | 33 (5.5%) | 74 (13.9%) | |
| Canada | 22 (3.6%) | 89 (16.7%) | |
| Other | 237 (39.2%) | 50 (9.4%) | |
| Cardiovascular Medications | |||
| Beta blocker | 497 (82.3%) | 471 (88.5%) | 0.003 |
| ACE inhibitor or ARB | 518 (85.8%) | 494 (92.9%) | <0.001 |
| Statin | 471 (78.0%) | 444 (83.5%) | 0.020 |
| Antiarrhythmic | 64 (10.6%) | 55 (10.3%) | 0.888 |
| Digoxin | 129 (21.4%) | 98 (18.4%) | 0.217 |
| Aspirin or Warfarin | 523 (86.6%) | 479 (90.0%) | 0.072 |
| Clopidogrel | 139 (23.0%) | 63(11.8%) | <0.001 |
| Diuretic | 419 (69.4%) | 434 (81.6%) | <0.001 |
| Nitrate | 364 (60.3%) | 245 (46.1%) | <0.001 |
| Previous ICD | 7 (1.2%) | 18 (3.4%) | 0.011 |
| Pacemaker for heart rate | 9 (1.5%) | 9 (1.7%) | 0.786 |
| Pacemaker for resynchronization | 4 (0.7%) | 2 (0.4%) | 0.690 |
| Clinical Endpoints* | |||
| Death | 226 (37.4%) | 215 (40.4%) | 0.234 |
| Death or CV hospitalization | 330 (54.6%) | 379 (71.2%) | <0.001 |
*
Comparisons based on log-rank test
BMI = body mass index; MI = myocardial infarction; PCI = percutaneous coronary intervention; CABG = coronary artery bypass grafting; CCS = Canadian Cardiovascular Society; NYHA = New York Heart Association; LAD = left anterior descending; LV = left ventricular; ESVI = end systolic volume index; United States; CV = cardiovascular